


Life Without Limitations





# ÖSSUR INVESTOR MEETING Q3 2010 26 October 2010





Life Without Limitations








## **HIGHLIGHTS Q3 2010**





# AMERICAS Q3 2010 - EXCELLENT B&S PERFORMANCE



#### Americas 55% of total sales

- •• Sales growth 11%
- Excellent B&S sales growth
  - Increased investment in sales platform
  - Successful new product launches
- Prosthetics slow quarter
  - Preparing the market for PROPRIO
  - Strong comparison

Note: All growth numbers in local currency including investments



#### EMEA Q3 2010 - MODERATE GROWTH





#### EMEA 40% of total sales

- Sales growth 3%
- B&S slow growth
  - New products not contributing as expected
  - Discontinued product lines affecting growth
- Prosthetics growing above market growth
  - Gaining market share
- Compression therapy 2% growth

Note: All growth numbers in local currency including investments

## ASIA Q3 2010 - UNUSUAL QUARTER



#### Asia 5% of total sales

- Sales decline 1%
- •• B&S
  - Strong sales in Australia
  - Increased penetration in new markets
- Prosthetics
  - Impacted by reimbursement review in Japan
- •• Good prospects for Q4

Note: All growth numbers in local currency



## **SUCCESSFUL B&S PRODUCT PIPELINE**




#### **Product launches YTD:**

#### Miami Lumbar belt



Miami J Advanced







**Rebound Walker** 








Innovator DLX



•• **Q1** 











•• **Q2** 

# **PROSTHETIC PRODUCT PIPELINE REMAINS STRONG**

ÖSSUR.

#### Product launches YTD:



Flex-Foot Balance





Total Knee 1100





Total Knee 2100




•• Q1







Life Without Limitations






# FINANCIALS Q3 2010 HJÖRLEIFUR PÁLSSON CFO



## **FINANCIAL HIGHLIGHTS Q3 2010**





- Good overall growth
- Expanding sales coverage
- Material exchange rate differences
- Solid profits and cash flow




Income Statements (USD millions)	Q3 2010	% of sales	Q3 2009	% of sales	Change	%change
Netsales	87.4	100.0%	84.2	100.0%	3.2	3.8%
Gross profit	54.4	62.3%	51.7	61.4%	2.7	5.2%
Operating expenses	-38.7	-44.3%	-36.8	-43.7%	-1.9	5.2%
Profit from operations	15.7	18.0%	14.9	17.7%	0.8	5.4%
Financial income / (expenses)	-10.4	-11.9%	-8.2	-9.7%	-2.2	26.9%
Net profit	4.0	4.6%	4.8	5.7%	-0.8	-16.7%
EBITDA	19.1	21.8%	19.4	23.0%	-0.3	-1.5%
EBITDA adjusted*	19.7	22.5%	19.4	23.0%	0.3	1.5%

\*Adjusted for one-time items:


USD m	Gains	Expenses	Net effect
Q3 2010	0	0.6	0.6
Q3 2009	0	0	0

#### SALES – MODERATE ORGANIC GROWTH



Note: Organic LCY growth excludes acquisitions








Sales by region / segments	Growth USD	Growth LCY	Organic growth LCY *
Americas	11%	11%	6%
EMEA	-5%	3%	3%
Asia	1%	-1%	-1%
Total	4%	7%	4%
Prosthetics	0%	3%	3%
Bracing and supports	9%	12%	6%
Compression therapy	-5%	5%	2%
Total	4%	7%	4%

\* Excluding acquired entities

#### **GROSS PROFIT – CONSISTENT**








#### **OPERATING EXPENSES – STABLE**






#### **EXCHANGE RATE MOVEMENTS – VOLATILE**






#### FINANCIAL ITEMS: NET EXCHANGE RATE DIFFERENCES



#### **NET PROFIT – IMPACTED BY EXCHANGE RATES**








#### EBITDA MARGIN – 23%







# **CASH FLOW – SOLID CASH GENERATION**




CASH GENERATED BY OPERATIONS 33% 35 29% 29.3 21% 30 20% 13% 24.2 25 **USD** millions 18.9 20 17.4 15 11.4 10 5 0 Q3 2009 Q1 2010 Q4 2009 Q2 2010 Q3 2010 Cash generated by operations — % of sales



#### **CAPEX – BELOW BENCHMARK**







#### **BALANCE SHEETS 30 SEPTEMBER 2010**




USD '000	30. Sept '10	31. Dec '09
Non current assets	434,841	448,446
Current assets	170,543	179,771
Total assets	605,384	628,217
Stockholders' equity	334,554	312,223
Non current liabilities	196,940	237,045
Current liabilities	73,890	78,949
Total equity and liabilities	605,384	628,217
Current ratio	2.3	2.3
Equity ratio	55%	50%
Net interest bearing debt / EBITDA	1.7	2.4
Debt/EBITDA	2.6	3.5



## FINANCIAL HIGHLIGHTS Q3 2010







- Good overall growth
- Expanding sales coverage
- Material exchange rate differences
- Solid profits and cash flow



Life Without Limitations







n

**Guidance** – Management estimates LCY organic sales growth for 2010 to be within the original guided range of 4-6%. EBITDA LCY organic growth is now estimated to be in the range of 5-7% for the year.




Sales growth organic (LCY): 4 - 6% EBITDA growth organic (LCY): 5 - 7%





Life Without Limitations







n

### **INCOME STATEMENTS Q3 2010**



Income Statements (USD millions)	Q3 2010	% of sales	Q3 2009	%of sales	Chang	ge
Netsales	87.4	100.0%	84.2	100.0%	3.2	3.8%
Cost of goods sold	-33.0	-37.7%	-32.5	-38.6%	-0.5	1.5%
Gross profit	54.4	62.3%	51.7	61.4%	2.7	5.2%
Other income	0.1	0.1%	0.0	0.0%	0.1	-
Sales and marketing	-23.0	-26.3%	-21.9	-26.1%	-1.1	5.0%
Research and development	-4.7	-5.4%	-4.2	-5.0%	-0.5	11.9%
General and administrative	-11.1	-12.7%	-10.7	-12.7%	-0.4	3.7%
Profit from operations	15.7	18.0%	14.9	17.7%	0.8	5.4%
Financial income	0.1	0.1%	0.0	0.1%	0.1	-
Financial expenses	-4.0	-4.6%	-4.0	-4.8%	0.0	0.0%
Net exchange rate difference	-6.5	-7.4%	-4.2	-5.0%	-2.3	54.8%
Profit before tax	5.3	6.1%	6.7	8.0%	-1.4	-20.9%
Income tax	-1.3	-1.5%	-1.9	-2.3%	0.6	-31.6%
Net profit	4.0	4.6%	4.8	5.7%	-0.8	-16.7%
EBITDA	19.1	21.8%	19.4	23.0%	-0.3	-1.5%
EBITDA adjusted*	19.7	22.5%	19.4	23.0%	0.3	1.5%
Adjusted for one-time items: USD m Gains Expenses Net effect Q3 2010 0 0.6 0.6						

Q3 2009

0

0

0

## **INCOME STATEMENTS YTD 2010**



Income Statements (USD millions)	YTD 2010	% of sales	YTD 2009	% of sales	Change	
Netsales	263.9	100.0%	242.7	100.0%	21.2	8.7%
Cost of goods sold	-99.8	-37.8%	-93.9	-38.7%	-5.9	6.3%
Gross profit	164.1	62.2%	148.8	61.3%	15.3	10.3%
Other income	1.6	0.6%	0.4	0.2%	1.2	300.0%
Sales and marketing	-71.4	-27.0%	-69.1	-28.5%	-2.3	3.3%
Research and development	-14.6	-5.5%	-13.9	-5.7%	-0.7	5.0%
General and administrative	-33.8	-12.8%	-31.6	-13.0%	-2.2	7.0%
Profit from operations	45.9	17.4%	34.5	14.2%	11.4	33.0%
Financial income	0.3	0.1%	0.2	0.1%	0.1	50.0%
Financial expenses	-11.7	-4.4%	-11.5	-4.7%	-0.2	1.7%
Net exchange rate difference	1.9	0.7%	-3.5	-1.4%	5.4	-154.3%
Profit before tax	36.4	13.8%	19.7	8.1%	16.7	84.8%
Income tax	-9.1	-3.4%	-5.0	-2.1%	-4.1	82.0%
Net profit	27.3	10.3%	14.7	6.1%	12.6	85.7%
EBITDA	56.5	21.4%	49.2	20.3%	7.3	14.8%
EBITDA adjusted*	56.3	21.3%	50.9	21.0%	5.4	10.6%
*Adjusted for one-time items:						
USD m Gains Expenses Net effect 2010 -1.3 1.1 -0.2						

2009

0

1.7

1.7

